GCCL (Global Clinical Central Lab) announced on September 18 that it will participate with an exclusive booth at Korea’s largest bio convention, BioPlus-InterPhex Korea 2025 (BIX 2025), held at COEX from October 15 to 17. On October 16, GCCL will also host a standalone IR Pitching & Networking Event.

Organized by the Korea Bio, BIX 2025 will feature keynote speeches, professional sessions, exhibitions, partnering meetings, and receptions. This year, 300 companies from 15 countries are expected to participate, with over 550 booths—the largest scale in the event’s history.

On the second day of the event, Thursday, October 16 at 4:00 PM, GCCL will host the “IR Pitching & Networking Event with GCCL” at Studio 159, 2nd floor, COEX. The event will bring together around 100 participants, including domestic and international pharma and biotech companies as well as investors, offering an opportunity to explore innovative technologies, business models, and potential strategic partnerships. The event will feature IR presentations from pharma and biotech companies along with open networking, and registration for participation is currently open.

During the exhibition, GCCL will operate a large exclusive booth to introduce its all-in-one solutions encompassing Central Lab, Bioanalysis, and R&D for global clinical trial sample analysis. Leveraging extensive experience collaborating with domestic and international drug developers, GCCL will highlight its strengths in providing a reliable, integrated analysis service covering sample transportation, analysis, and data management.

Notably, GCCL will present a new interactive lab tour using touchscreens, enabling visitors to intuitively experience GCCL’s analysis processes and services. With full GCLP (Good Clinical Laboratory Practice) certification, advanced analytical equipment, and optimized IT systems, GCCL emphasizes its competitive capabilities based on international quality standards, further strengthening its differentiated positioning and expertise in the global clinical trial market.

CEO KwanGoo Cho stated, “BIX 2025 provides a significant platform to directly engage with the global pharma and biotech community and showcase GCCL’s expertise and integrated analysis solutions. Through the IR Pitching & Networking Event, we aim to expand strategic partnerships with domestic and international companies and further enhance GCCL’s global competitiveness in clinical trial sample analysis.”

GCCL is a clinical trial sample analysis organization certified across all areas of the Ministry of Food and Drug Safety’s GCLP standards, offering tailored clinical analysis services that meet global standards for all phases of clinical trials, from Phase I to Phase IV. Leveraging diverse analytical platforms and professional sample analysis and method development services compliant with global quality standards, including ddPCR systems, GCCL supports clinical trial sample analysis for domestic pharma and biotech companies as well as partners across Asia and worldwide.